Edition:
United States

Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

17.85USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$17.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
339,871
52-wk High
$25.70
52-wk Low
$7.80

Select another date:

Fri, Dec 8 2017

BRIEF-Impax Receives Tentative fda Approval Of Generic Coreg CR (Carvedilol Phosphate) Extended-Release Capsules

* IMPAX RECEIVES TENTATIVE FDA APPROVAL OF GENERIC COREG CR® (CARVEDILOL PHOSPHATE) EXTENDED-RELEASE CAPSULES

BRIEF-Impax Laboratories says co entered into amendment no. 1 to business combination agreement with Atlas Holdings ​

* Impax Laboratories Inc - ‍on Nov 21, co entered into amendment no. 1 to business combination agreement, dated October 17, 2017 with Atlas Holdings ​

BRIEF-Impax Laboratories says board of co amended and restated bylaws of co

* Impax Laboratories says ‍on and effective Nov 10, 2017, board of co amended and restated bylaws of company - SEC filing

BRIEF-Impax Q3 adjusted earnings per share $0.23

* Q3 earnings per share view $0.20 -- Thomson Reuters I/B/E/S

BRIEF-Impax gets FDA approval for generic Renvela tablets

* Impax announces FDA approval and launch of generic Renvela (sevelamer carbonate) tablets, 800 mg

UPDATE 3-Amneal, Impax combine to tackle generic drug pricing pressure

* Impax was expected to keep >25 pct stake - analyst (Adds analysts' comments, background on retail pharmacies; updates shares)

BRIEF-IMPAX TO PAY AMNEAL $45 MLN IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES‍​

* REQUIRED TO PAY AMNEAL FEE OF $45 MILLION IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES‍​

Drugmakers Amneal, Impax to combine in generics push

Amneal Pharmaceuticals LLC is buying peer Impax Laboratories Inc in an all-stock deal as it looks to add heft to its generics business and gain an edge in a tough drug pricing environment.

BRIEF-Drugmaker Amneal to combine with Impax Labs

* Transaction expected to generate $200 million of annual cost savings within three years​

Drugmakers Amneal and Impax to combine

Oct 17 Privately-held generic drugmaker Amneal Pharmaceuticals LLC and peer Impax Laboratories Inc said on Tuesday they would combine in an all-stock transaction.

Select another date: